Introduction {#S0001}
============

Quality of life (QoL) has not been clearly defined up to date, although it is clear that it is a subjective self-assessment that to a significant extent is determined by individual needs, beliefs, values, attitudes, which are changing with time. In medical sciences, Schipper has introduced a concept of a health-related QoL \[[@CIT0001]\]. QoL comprises basic dimensions such as patients' performance status, physical, emotional, and social functioning, symptoms of the disease and adverse effects (AE) of the treatment. QoL refers also to spiritual (existential and God) and other dimensions, for example body image changes. In the general QoL assessment that is determined by the health status, apart from the symptoms of the disease and AE of the treatment, the attitude of patients to themselves, their own disease and ways of coping with the disease are taken into account \[[@CIT0002]\].

When evaluating QoL special attention is paid to the necessity to differentiate between an objective assessment of the health status (clinical staging, diagnosis, symptom intensity, limitations in physical and social functioning due to the disease) and a subjective QoL assessment. The subject of QoL is not an objective evaluation of the disease status but a subjective patients' self-assessment of their life \[[@CIT0003]--[@CIT0006]\]. QoL evaluation is normally conducted subjectively, from the patients' perspective. If patients cannot assess their QoL, then proxies (physicians, nurses, carers) may do that. QoL evaluation has a positive impact on the patients, families and carers' well-being and also improves patients' satisfaction from care provided and improves the process of the adaptation to a disease.

Factors influencing quality of life of women with different localization of gynecological cancer {#S0002}
================================================================================================

Tumors of the ovary and oviduct {#S20003}
-------------------------------

The main method of the management of ovary and oviduct tumors is surgical intervention and systemic treatment, which significantly influence women\'s QoL. A surgical intervention comprises resection of the uterus, both ovaries, greater omentum, appendix and local lymph nodes, and in the case of an unresectable tumor, a maximal cytoreduction is conducted \[[@CIT0007], [@CIT0008]\]. After ovariectomy in premenopausal women, QoL is significantly deteriorated by infertility and a sudden appearance of menopausal symptoms due to the decrease in the level of sex hormones in the blood serum, predominantly estrogens. The intensity of menopausal symptoms is different depending on the individual patient but in most cases it significantly decreases a sense of well-being. Apart from subjective symptoms, menopause objectively disturbs bone and vessel wall metabolism, which increases the risk of osteoporosis development and possibility of bone fractures and vascular episodes, which may all significantly deteriorate QoL \[[@CIT0009]\].

The systemic treatment (most commonly chemotherapy with platinum derivatives and taxanes) may induce nausea, vomiting, lack of appetite, alopecia, weakness and fatigue. In spite of the burden and the need of symptom prevention, the symptoms usually disappear within a few days after treatment completion. Symptoms of peripheral polyneuropathies may be more problematic in terms of management and more sustainable. Such symptoms appear during treatment with platinum derivatives and taxanes.

The most common symptoms in the advanced phase of ovary and oviduct cancer are as follows: ascites, abdominal and hypogastric pain often associated with the dissemination of the tumor in the abdomen. Apart from colicky pain, other symptoms comprise nausea and vomiting, difficulties in food consumption, constipation, weakness and fatigue, which may accompany the anorexia-cachexia-asthenia syndrome. The listed symptoms may intensify significantly in patients with bowel obstruction \[[@CIT0010]\].

Tumors of uterus cervix and corpus {#S20004}
----------------------------------

The management of cervix and corpus uterus cancer is based usually on surgical interventions and radiotherapy and the observed AE are associated with the type of the treatment applied. In patients classified as IA according to FIGO (Féderation Internationale de Gynécologie et d\'Obstétrique) with a well-differentiated tumor of uterus corpus type I (endometrioid adenocarcinoma) and in cases of squamous cell cancer G1 of the cervical cancer stage 0-IA, a surgical intervention is recommended and the observed QoL deterioration is relatively the least intense and usually a short-term phenomenon. In the rest of patients the possibility of both short- and long-term QoL deterioration is much bigger due to radiotherapy and/or chemotherapy. In cervix and corpus uterus cancer patients, most commonly adjuvant radiotherapy after surgery is administered and in the group of patients with endometrium cancer type II (non-endometrioid) systemic treatment is applied.

In patients with locally advanced cervical cancer (IIB--IIIB), the management of choice is radio-chemotherapy with platinum derivatives. In cervical and uterine corpus cancer stage IV, in whom QoL deterioration is induced by symptoms of tumor progression, the treatment is planned individually depending on the clinical situation \[[@CIT0011]--[@CIT0014]\].

In the case of surgical intervention, urine incontinence and other urinary system disturbances and sexual dysfunction may appear \[[@CIT0015]\]. Radiotherapy complications comprise changes in vaginal mucosa that may induce dyspareunia and make sexual activity difficult. Radiotherapy may induce adhesions, damage to the rectal and vagina mucosa, urinary symptoms and sexual problems. In consequence of radiotherapy, pain in the rectum intensifies during bowel movement, bowel dysfunction associated with a dissemination of cancer in the abdomen may lead to intestinal obstruction which demand surgical intervention. In a small percentage of patients undergoing radical radiotherapy, the complication of the treatment is development of fistulae in the pelvis, most commonly vesicovaginal or recto-vaginal fistula, which dramatically deteriorate QoL in patients with advanced cervical cancer. In the case of recto-vaginal fistula, in most patients the treatment of choice is colostomy development, which may also additionally deteriorate QoL \[[@CIT0016]\].

In the advanced period of the disease the most common symptoms of uterus tumors comprise pain in the hypogastrium usually associated with a local cancer progression in the pelvis and abdomen. Often, there are symptoms of neuropathic pain associated with the infiltration of nervous plexus. The development of cancer may be accompanied by several symptoms such as nausea, vomiting, lack of appetite, constipation, weakness, fatigue and cachexia. In patients with locally advanced cervical cancer, renal insufficiency may develop and it may be necessary to conduct nephrostomy for urine outflow. The symptom of a tumor development might be also colporrhagia, which in the case of endometrium cancer usually proceeds to cause other symptoms. In patients with squamous cell carcinoma, symptoms are rarely associated with distant metastases; it is typical of sarcoma that often metastasizes to lungs and induces dyspnea or other symptoms depending on the location.

Tumors of vagina and vulva {#S20005}
--------------------------

Due to the location of the tumor pain, problems with passing urine and sexual functioning may be present. It is not uncommon that intractable pruritus appears in spite of the treatment used. The management of vaginal cancer is mainly composed of radiotherapy, only in selected patients surgical intervention is conducted \[[@CIT0017]\]. In patients with vulva cancer the basic approach is surgery with adjuvant radiotherapy in some patients treated \[[@CIT0018]\]. In advanced stages of vagina and vulva cancer, a systemic treatment may also be applied. The treatment of vaginal and particularly vulva cancer is often associated with a significant damage that strongly deteriorates patients' QoL.

In the case of a diagnosis of a gynecological cancer in women, one should always take into account a negative impact of the disease on the emotional, social and spiritual functioning. This requires the staff caring for patients with gynecological cancer not only to provide appropriate medical (directed at the underlying disease and symptomatic) management of the disease but also comprehensive support in all patients' life dimensions. To achieve this aim it is necessary to use an interdisciplinary approach with the involvement of physicians, nurses, psychologists, social workers and volunteers and patients' families and carers.

Clinical practice recommendations for quality of life assessment {#S0006}
================================================================

Intensive QoL studies have led to the development of numerous precise and multidimensional tools in recent years, so the choice of the appropriate method of an assessment and monitoring of QoL by the clinician or researcher should depend on the general patients' condition and the aim of the measurement. In everyday clinical practice an assessment and monitoring of QoL seem to be a necessity similarly to the evaluation of other live parameters.

One of the possibilities of screening the psychological state of cancer patients is a distress thermometer that on a scale from 0 to 10 indicates no stress (0) to the strongest psychological distress (10) ([Fig. 1](#F0001){ref-type="fig"}) \[[@CIT0019], [@CIT0020]\]. The results of 0-4 do not require further interventions. However, when the score equals 5 or more, patients are asked a series of questions which comprise different live dimensions, which aims to establish the cause of the stress ([Fig. 2](#F0002){ref-type="fig"}). Explanations from a person talking with a patient regarding the questionnaire filling might be useful. An additional screening tool for detecting psychological disturbances might be a Hospital Anxiety and Depression Scale (HADS) which was supplemented in the Polish version with two questions regarding anger \[[@CIT0021]\].

![The distress thermometer](MR-14-26406-g001){#F0001}

![Questions for patients with a score of 5 or more on the distress thermometer](MR-14-26406-g002){#F0002}

For QoL assessment made once (conducted in the evening) or twice daily (performed in the morning and in the evening) for patients staying at in-patient units, an Edmonton Symptom Assessment System (ESAS) questionnaire is recommended. ESAS is a simple tool possessing good psychometric properties and can be filled in by the patient within a short time. Results obtained may be shown in a graphic form that resembles the temperature or heart rate plot measured in the morning and in the evening on consecutive days of a stay at an in-patient unit \[[@CIT0022]--[@CIT0025]\]. In patients in an ambulatory care setting, QoL assessment is conducted with the ESAS questionnaire during each patients' visit in an out-patient clinic and in home care, most often twice a week during nurses' visits.

For QoL assessment within clinical trials, a core questionnaire EORTC QLQ-C30 is conducted for patients during oncological treatment \[[@CIT0026]\], which is supplemented with modules for given locations of the primary tumor e.g. cervical, ovary and endometrial cancer \[[@CIT0027]--[@CIT0029]\]. QoL assessment in patients using the aforementioned questionnaires is conducted most commonly every 7 days. An alternative tool might be the Rotterdam Symptom Checklist (RSCL) in which AE of radiotherapy and chemotherapy are included \[[@CIT0030]\]. In patients with advanced cancer under palliative care it is usually recommended to conduct the EORTC QLQ-C15-PAL questionnaire once a week. This questionnaire focuses mainly on physical symptoms and global QoL \[[@CIT0031]\]. For the purpose of non-commercial clinical trials, EORTC questionnaires might be downloaded for free from the web page of the EORTC Quality of Life Group (<http://groups.eortc.be/qol/>).

Selected quality of life assessment instruments for cancer patients {#S0007}
===================================================================

The Hospital Anxiety and Depression Scale (HADS) {#S20008}
------------------------------------------------

The questionnaire is devoted to screening of anxiety and depression in patients hospitalized in non-psychiatric departments. The original version of the tool consists of 7 questions regarding anxiety and 7 questions exploring depression. In a modified Polish version, 2 questions were added concerning irritability and aggression, which increased the usefulness of the tool as a separate method of exploration of patient\'s emotional reaction to the disease ([Fig. 3](#F0003){ref-type="fig"}). The tool is short, easy to use and interpret \[[@CIT0021]\].

![The Modified Hospital Anxiety and Depression Scale (HADS)](MR-14-26406-g003){#F0003}

European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire -- Core 30 (EORTC QLQ-C30) {#S20009}
-----------------------------------------------------------------------------------------------------------------------

EORTC QLQ-C30 ([Fig. 4](#F0004){ref-type="fig"}) was elaborated by the Quality of Life Group of the European Organization for the Research and Treatment of Cancer (EORTC) as a core questionnaire and a part of the modular approach and multidimensional measurement of QoL in cancer patients \[[@CIT0026]\]. A more precise QoL assessment depending on the location of the primary tumor may be conducted together with the EORTC QLQ-C30 or with the EORTC QLQ-C15-PAL ([Fig. 5](#F0005){ref-type="fig"}) module for patients with cervical cancer (EORTC QLQ-CX24) ([Fig. 6](#F0006){ref-type="fig"}), ovarian cancer (EORTC QLQ-OV28) ([Fig. 7](#F0007){ref-type="fig"}), and endometrial cancer (EORTC QLQ-EN24) ([Fig. 8](#F0008){ref-type="fig"}) adapted to Polish \[[@CIT0027]--[@CIT0029]\].

![The EORTC QLQ--C30 (version 3)](MR-14-26406-g004){#F0004}

![The EORTC QLQ--C15--PAL (version 1)](MR-14-26406-g005){#F0005}

![The EORTC QLQ-CX24 questionnaire](MR-14-26406-g006){#F0006}

![The EORTC QLQ-OV28 questionnaire](MR-14-26406-g007){#F0007}

![The EORTC QLQ-EN24 questionnaire](MR-14-26406-g008){#F0008}

The EORTC QLQ-C30 contains questions about how the disease influences patients' functioning (functional scales) and how symptoms impact patients' QoL (symptom scales). The functional scales comprise physical functioning, role functioning (work), emotional, cognitive and social functioning and global QoL. The symptom scales consist of fatigue, nausea and vomiting, and pain scales and single items of dyspnea, sleep disturbances, lack of appetite, constipation, diarrhea and the impact of the disease on finances. In the majority of questions of the EORTC QLQ-C30, a 4-step Likert scale is used; in 2 questions regarding health status and global QoL, a 7-step scale was used.

European Organization for Research and Treatment of Cancer Quality of Life Questionnaire -- Core 15 -- Palliative Care (EORTC QLQ-C15-PAL) {#S20010}
------------------------------------------------------------------------------------------------------------------------------------------

A shorter version of the EORTC QLQ-C30 questionnaire was elaborated, devoted to patients with advanced cancer, which comprises 15 questions (the EORTC QLQ-C15-PAL) \[[@CIT0031]\]. The EORTC QLQ-C15-PAL questionnaire was adapted to Polish \[[@CIT0032]\].

The Rotterdam Symptom Checklist (RSCL) {#S20011}
--------------------------------------

The tool consists of 30 items regarding symptoms and 8 questions concerning patients' everyday activity ([Fig. 9](#F0009){ref-type="fig"}). Based on the factor analysis two dimensions were found: psychological and physical. The psychological factor is composed of irritability, worrying, depressed mood, nervousness, desperate feelings about the future, tension, anxiety and difficulty concentrating. For the physical factor all other items were included. RSCL comprises the impact of the cancer treatment on psychosocial functioning of patients and it is a valid (with appropriate validity and reliability) instrument for the assessment of psychological, social, professional and physical domains of patients' QoL \[[@CIT0030]\].

![The Rotterdam Symptom Checklist (RSCL)](MR-14-26406-g009){#F0009}

Edmonton Symptom Assessment System (ESAS) {#S20012}
-----------------------------------------

Edmonton Symptom Assessment System in the original version is composed of 10 visual-analogue scales, depicted on the left as the least intensity or lack of a symptom and at the right as the most severe intensity of a symptom. The patient marks in her opinion the most appropriate place on the scale of pain, activity, nausea, depression, anxiety, drowsiness, appetite, well-being, dyspnea, and one additional symptom mentioned by the patient \[[@CIT0022]\]. In the Polish modified version, two frequent symptoms encountered in palliative care patients were added: constipation and vomiting ([Fig. 10](#F0010){ref-type="fig"}). ESAS may be filled in in a few minutes; it may be conducted in hospital departments mostly twice daily. ESAS is a validated tool with appropriate validity and reliability. The currently recommended version of the ESAS is the so called ESAS-revised (ESAS-r), which compared to the original version contains fatigue instead of activity; the evaluation is conducted using numerical scales from 0 (lack of a symptom) to 10 (the most severe symptom intensity \[[@CIT0023]\].

![The Modified Edmonton Symptom Assessment System (revised version) (ESAS-r)](MR-14-26406-g010){#F0010}

Conclusions {#S0013}
===========

QoL evaluation makes it possible to obtain important information from patients regarding not only symptoms of the disease, AE of the treatment but also psychological, social and spiritual dimensions. QoL assessment conducted in gynecological cancer patients should take into account many burdensome symptoms, which negatively influence patients' QoL. The instruments used should be short and easy to understand and those conducting the evaluation should pay attention to clinical staging of the patients. Apart from everyday clinical practice, QoL assessment is a significant part of clinical trials and a source of progress in the oncological treatment and symptomatic management of cancer. One of the important aims of cancer management is improvement and maintenance of the highest QoL possible in cancer patients, especially in those with advanced disease and in their families and carers.
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